Stock Quote
No news stories for this company within the last 30 days.
OSCI.OQ
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Stone, David | Chairman of the Board | -- |
| Rauscher, Stephen | President, Chief Executive Officer, Director | 696,393 |
| Maitre, Philippe | Chief Financial Officer, Executive Vice President | 507,718 |
Profile
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing United States Food and Drug Administration (FDA) approved products in the United States. The Company markets two products: ANTARA (fenofibrate) capsules, a cardiovascular product, and FACTIVE (gemifloxacin... Full Description
Company Address
Oscient Pharmaceuticals Corporation
1000 Winter Street
Suite 2200
Waltham MA 02451
P: +1781.3982300
F: +1781.8939535
1000 Winter Street
Suite 2200
Waltham MA 02451
P: +1781.3982300
F: +1781.8939535
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Lupin Limited | Rs1,373.65 | +43.55 |
| Shionogi & Co., Ltd. | ¥1,848.00 | +46.00 |
| Teva Pharmaceutical Industries Limited | ₪19,990.00 | -210.00 |
| OSCI.OQ | Industry | |
|---|---|---|
| P/E(TTM) | -- | 3.65 |
| P/S(TTM) | 0.01 | 0.56 |
| ROI(TTM) | -78.66 | 1.86 |
| ROE(TTM) | -- | 2.52 |
| Consensus Recommendation | |
|---|---|
| EPS Est. (Current Period) | -- |
| EPS Est. (Current Year) | -- |
| Total Revenue | $26.41M |
| Net Income | $-11.53M |
| EPS | $-0.50 |
